Philips shared the results of tests conducted on a sample of sleep apnea devices from the US and Canada, wherein the majority of the devices passed volatile organic compound and respirable particulate emission testing. While the firm’s guidance for healthcare providers and patients with respect to the device use was unchanged, the prospect of newer damaging newsflow has a low probability, with the stock (consolidating at 2016 lows) offering a healthy upside, especially considering the easing Chi ....
28 Jun 2022
A promising(?) update on recalled sleep apnea devices
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A promising(?) update on recalled sleep apnea devices
Philips shared the results of tests conducted on a sample of sleep apnea devices from the US and Canada, wherein the majority of the devices passed volatile organic compound and respirable particulate emission testing. While the firm’s guidance for healthcare providers and patients with respect to the device use was unchanged, the prospect of newer damaging newsflow has a low probability, with the stock (consolidating at 2016 lows) offering a healthy upside, especially considering the easing Chi ....